Bigul

Dr. Lal PathLabs Ltd - 539524 - Statement Of Investor Complaints For The Quarter Ended September 2022

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 055550 Name of the Signatory :- Rajat KalraDesignation :- Company Secretary and Compliance Officer
12-10-2022

Will Stocks Like IEX, IRCTC, And Dr Lal Pathlabs Ever Recover?

What's ailing stocks like IEX, IRCTC, and Dr Lal Pathlabs?
11-10-2022

Dr. Lal PathLabs Ltd - 539524 - Closure of Trading Window

We wish to inform you that as per the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's code for Prevention of Insider Trading, the Trading Window, shall be closed from October 1, 2022 and would be re-opened after 48 hours from the date of announcement / declaration of Financial Results for the Quarter and Half Year ending September 30, 2022. We request you to kindly take the same on record.
30-09-2022

Why Dr Lal PathLabs November futures trade in deep discount?

Price behaviour puzzles analysts as 'It defies any logic'
29-09-2022

Trade Spotlight | What should you do with India Cements, Dr Lal PathLabs, Glenmark Pharma on Thursday?

Dr Lal PathLabs shares gained 1.7 percent to Rs 2,694.35, continuing uptrend for the seventh consecutive session. It has seen formation of bullish candle on the daily charts with higher high higher low formation for seven straight sessions, and has given a breakout of downward sloping resistance trend line adjoining April 8 and August 26.
29-09-2022